Skip to content

Precigen PGEN Book value per share

Book value per share at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$291.77+10.4%
Gilead Sciences logo
Gilead SciencesGILD
$18.75+23.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$7.43-22.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$18.87-26.1%
Arrowhead Research logo
Arrowhead ResearchARWR
$4.31-15.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$2.35-257%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Calculated from Precigen’s reported figures.

Based on the most recent quarter.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's book value per share?
Precigen (PGEN) reported book value per share of $0.06 in Q1 2026.
How has Precigen's book value per share changed year-over-year?
Precigen's book value per share increased by 219.5% year-over-year, from -$0.05 to $0.06.
What is the long-term trend for Precigen's book value per share?
Over 5 years (2020 to 2025), Precigen's book value per share has grown at a -30.2% compound annual growth rate (CAGR), from $0.40 to $0.07.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.